Insight Molecular Diagnostics Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -3.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.23 | not reported | not reported | |
| Q1 FY26 | $-0.26 | $-0.28 | -7.1% | Miss | Q1 FY26 call · transcript |
| Q4 FY25 | not reported | $-0.27 | not reported | not reported | |
| Q3 FY25 | not reported | $-0.34 | not reported | not reported | |
| Q2 FY25 | not reported | $-0.30 | not reported | not reported | |
| Q1 FY25 | not reported | $-0.26 | not reported | not reported | |
| Q4 FY24 | not reported | $0.48 | not reported | not reported | |
| Q3 FY24 | not reported | $-0.98 | not reported | not reported | |
| Q2 FY24 | not reported | $-0.36 | not reported | not reported | |
| Q1 FY24 | not reported | $-1.13 | not reported | not reported | |
| Q3 FY23 | not reported | $-0.57 | not reported | not reported | |
| Q2 FY23 | $-2.60 | $-1.07 | +58.9% | Beat |
Back to IMDX overview · IMDX holders · IMDX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.